Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

24 matching registry records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:39 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2RecruitingINTERVENTIONAL

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

ClinicalTrials.gov · NCT06554717 · Registry updated: 2026-05-19

Condition / research focus: HIV-1-infection; Frailty; Impaired Physical Function; Abdominal Obesity; Aging
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2025-07-10. Completion: 2028-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug) — also listed as: Egrifta, TH9507, growth hormone-releasing hormone analogue
Placebo (drug)
Exercise (behavioral)

Where the study takes place — 2 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

University of Colorado - Anschutz Medical Campus
Aurora, Colorado, United States
Site recruitment: Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Body Composition and Adipose Tissue in HIV

ClinicalTrials.gov · NCT03226821 · Registry updated: 2026-05-19

Condition / research focus: HIV Lipodystrophy Syndrome; Growth Hormone Deficiency; Body Composition
Sponsor: Columbia University
Countries with listed sites: United States
Registry dates and results: Start: 2018-02-07. Completion: 2025-04-30 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug) — also listed as: Egrifta

Where the study takes place — 1 listed sites

Neuroendocrine Unit and Pituitary Center, Columbia University
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

ClinicalTrials.gov · NCT07481734 · Registry updated: 2026-03-19

Condition / research focus: Metabolic Associated Steatotic Liver Disease; Nonalcoholic Steatohepatitis; Hepatic Steatosis
Sponsor: Hudson Biotech
Countries with listed sites: China
Registry dates and results: Start: 2026-02-02. Completion: 2028-02-17 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug)
Placebo (drug)
Standardized lifestyle counseling (behavioral)

Where the study takes place — 1 listed sites

Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

ClinicalTrials.gov · NCT02572323 · Registry updated: 2026-03-12

Condition / research focus: Mild Cognitive Impairment
Sponsor: University of California, San Diego
Countries with listed sites: United States
Registry dates and results: Start: 2017-02-15. Completion: 2023-10-15 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug) — also listed as: Egrifta

Where the study takes place — 4 listed sites

Keck School of Medicine of the University of Southern California
Los Angeles, California, United States
Site recruitment: Not reported
PalmTree
Palm Springs, California, United States
Site recruitment: Not reported
HIV Neurobehavioral Research Program (HNRP)
San Diego, California, United States
Site recruitment: Not reported
University of California, San Francisco
San Francisco, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

ClinicalTrials.gov · NCT03375788 · Registry updated: 2025-11-20

Condition / research focus: Non-Alcoholic Fatty Liver Disease; Obesity; Obesity, Abdominal; Liver Fat; Fatty Liver
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2019-01-17. Completion: 2025-01-10 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug) — also listed as: Egrifta, TH9507, Growth Hormone Releasing Hormone Analog
Identical Placebo (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

ClinicalTrials.gov · NCT03150511 · Registry updated: 2025-11-12

Condition / research focus: Peripheral Nerve Injuries
Sponsor: Johns Hopkins University
Countries with listed sites: United States
Registry dates and results: Start: 2018-06-01. Completion: 2027-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin 2 Milligrams (MG) (drug) — also listed as: Egrifta

Where the study takes place — 1 listed sites

Sami Tuffaha
Baltimore, Maryland, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

ClinicalTrials.gov · NCT00608023 · Registry updated: 2022-09-30

Condition / research focus: Lipodystrophy; HIV Infections
Sponsor: Theratechnologies
Countries with listed sites: Belgium · Canada · France · Spain · United Kingdom · United States
Registry dates and results: Start: 2007-08. Completion: 2008-10 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug) — also listed as: Egrifta
Placebo for Tesamorelin (drug)

Where the study takes place — 47 listed sites

University of Alabama at Birmingham
Birmingham, Alabama, United States
Site recruitment: Not reported
Body Positive Inc.
Phoenix, Arizona, United States
Site recruitment: Not reported
Somero, Michael
Indio, California, United States
Site recruitment: Not reported
UCLA School of Medicine
Los Angeles, California, United States
Site recruitment: Not reported
Office of Dr. Michael Somero
Palm Springs, California, United States
Site recruitment: Not reported
University of California
San Francisco, California, United States
Site recruitment: Not reported
Kaiser Permanente
San Francisco, California, United States
Site recruitment: Not reported
UCSF/VA Medical Center
San Francisco, California, United States
Site recruitment: Not reported
AIDS Research Alliance
West Hollywood, California, United States
Site recruitment: Not reported
Denver Public Health Department
Denver, Colorado, United States
Site recruitment: Not reported
Office of Dr. Gary Richmond
Fort Lauderdale, Florida, United States
Site recruitment: Not reported
Hendry/Glades County Health Departments
LaBelle, Florida, United States
Site recruitment: Not reported
Infectious Disease Research Institute Inc.
Tampa, Florida, United States
Site recruitment: Not reported
AIDS Research Consortium Atlanta (ARCA)
Atlanta, Georgia, United States
Site recruitment: Not reported
Northern Healthcare
Chicago, Illinois, United States
Site recruitment: Not reported
Northstar Medical
Chicago, Illinois, United States
Site recruitment: Not reported
Indiana University Department of Medicine
Indianapolis, Indiana, United States
Site recruitment: Not reported
Tufts University School of Medicine
Boston, Massachusetts, United States
Site recruitment: Not reported
Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
The Research Institute
Springfield, Massachusetts, United States
Site recruitment: Not reported
ID Associates
Hillsborough, New Jersey, United States
Site recruitment: Not reported
AIDS Community Research Initiative of America
New York, New York, United States
Site recruitment: Not reported
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Site recruitment: Not reported
University Hospitals of Cleveland
Cleveland, Ohio, United States
Site recruitment: Not reported
Central Texas Clinical Research
Austin, Texas, United States
Site recruitment: Not reported
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States
Site recruitment: Not reported
Swedish Medical Center
Seattle, Washington, United States
Site recruitment: Not reported
C. H. U. Sart-Tilman
Liège, Belgium
Site recruitment: Not reported
St-Paul's Hospital
Vancouver, British Columbia, Canada
Site recruitment: Not reported
McMaster University Health Sciences Centre
Hamilton, Ontario, Canada
Site recruitment: Not reported
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Site recruitment: Not reported
Toronto General Hospital
Toronto, Ontario, Canada
Site recruitment: Not reported
Centre Hospitalier Universitaire de Santé de l'Estrie
Fleurimont, Quebec, Canada
Site recruitment: Not reported
Montreal General Hospital
Montreal, Quebec, Canada
Site recruitment: Not reported
Groupe de Recherche en Rhumatologie et maladies osseuses
Ste-Foy, Quebec, Canada
Site recruitment: Not reported
Hôpital Hotel Dieu Lyon
Lyon, France
Site recruitment: Not reported
Hotel Dieu
Nantes, France
Site recruitment: Not reported
Hopital Europeen Georges Pompidou
Paris, France
Site recruitment: Not reported
Hopital Necker
Paris, France
Site recruitment: Not reported
Hosp. Ramon y Cajal
Madrid, Spain
Site recruitment: Not reported
Hosp. Clinico San Carlos
Madrid, Spain
Site recruitment: Not reported
Hosp.C.U.de Santiago
Santiago de Compostela, Spain
Site recruitment: Not reported
BSUH NHS Trust
Brighton, United Kingdom
Site recruitment: Not reported
St Georges Hospital
London, United Kingdom
Site recruitment: Not reported
Royal Free Hospital
London, United Kingdom
Site recruitment: Not reported
Chelsea and Westminster Hospital
London, United Kingdom
Site recruitment: Not reported
St Mary's NHS Trust
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Growth Hormone Dynamics and Cardiac Steatosis in HIV

ClinicalTrials.gov · NCT03826160 · Registry updated: 2022-07-19

Condition / research focus: Human Immunodeficiency Virus; Lipodystrophy; Cardiac Disease
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2019-01-30. Completion: 2022-04-19 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting

ClinicalTrials.gov · NCT01388920 · Registry updated: 2022-03-18

Condition / research focus: Chronic Obstructive Pulmonary Disease (COPD)
Sponsor: Theratechnologies
Countries with listed sites: No country reported
Registry dates and results: Start: 2011-09. Completion: 2011-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Tesamorelin Effects on Liver Fat and Histology in HIV

ClinicalTrials.gov · NCT02196831 · Registry updated: 2020-01-27

Condition / research focus: Human Immunodeficiency Virus (HIV); Nonalcoholic Fatty Liver Disease (NAFLD); Nonalcoholic Steatohepatitis (NASH)
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2015-07-01. Completion: 2019-07-24 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

tesamorelin (drug) — also listed as: Egrifta
Placebo (drug)

Where the study takes place — 2 listed sites

National Institutes of Health
Bethesda, Maryland, United States
Site recruitment: Not reported
Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2WithdrawnINTERVENTIONAL

Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia

ClinicalTrials.gov · NCT02931474 · Registry updated: 2019-11-19

Condition / research focus: Sleep Disorder; Traumatic Brain Injury
Sponsor: National Institute of Nursing Research (NINR)
Countries with listed sites: No country reported
Registry dates and results: Start: 2016-10-06. Completion: 2017-03-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug)
Placebo (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

ClinicalTrials.gov · NCT02553603 · Registry updated: 2019-11-04

Condition / research focus: Mild Cognitive Impairment
Sponsor: The University of Texas Medical Branch, Galveston
Countries with listed sites: United States
Registry dates and results: Start: 2017-07-18. Completion: 2019-01-17 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Growth Hormone Releasing Hormone (GHRH) (drug) — also listed as: Egrifta, tesamorelin
Placebo Growth Hormone Releasing Hormone (drug) — also listed as: Placebo

Where the study takes place — 1 listed sites

The University of Texas Medical Branch
Galveston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

ClinicalTrials.gov · NCT01591902 · Registry updated: 2018-09-11

Condition / research focus: Diabetic Retinopathy; HIV
Sponsor: Theratechnologies
Countries with listed sites: United States
Registry dates and results: Start: 2012-06. Completion: 2018-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug)
Placebo-Control (drug)

Where the study takes place — 24 listed sites

Southwest Center for HIV/AIDS
Phoenix, Arizona, United States
Site recruitment: Not reported
Spectrum Medical Group
Phoenix, Arizona, United States
Site recruitment: Not reported
5P21 Rand Schrader Clinic
Los Angeles, California, United States
Site recruitment: Not reported
University of California CARE Clinic, Los Angeles
Los Angeles, California, United States
Site recruitment: Not reported
Palmtree Clinical Research, Inc.
Palm Springs, California, United States
Site recruitment: Not reported
UCSD Antiviral Research Center
San Diego, California, United States
Site recruitment: Not reported
VAMC, Infectious Disease Section 111W
San Francisco, California, United States
Site recruitment: Not reported
Capital Medical Associates, PC
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Gary J. Richmond, M.D., PA
Fort Lauderdale, Florida, United States
Site recruitment: Not reported
Orange County Health Department
Orlando, Florida, United States
Site recruitment: Not reported
Triple O Research Institute
West Palm Beach, Florida, United States
Site recruitment: Not reported
Rowan Tree Medical , P.A.
Wilton Manors, Florida, United States
Site recruitment: Not reported
Be Well Medical Center, P.C.
Berkley, Michigan, United States
Site recruitment: Not reported
Southampton Clinical Research, Inc d.b.a. Central West Clinical Research
St Louis, Missouri, United States
Site recruitment: Not reported
Southampton Healthcare, Inc.
St Louis, Missouri, United States
Site recruitment: Not reported
South Jersey Infectious Disease
Somers Point, New Jersey, United States
Site recruitment: Not reported
Harold Hamm Diabetes Center at the University of Oklahoma
Oklahoma City, Oklahoma, United States
Site recruitment: Not reported
Fanno Creek Clinic, LLC
Portland, Oregon, United States
Site recruitment: Not reported
Central Texas Clinical Research
Austin, Texas, United States
Site recruitment: Not reported
St. Hope Foundation, Inc.
Bellaire, Texas, United States
Site recruitment: Not reported
Dallas VA Medical Center
Dallas, Texas, United States
Site recruitment: Not reported
UT Southwestern Medical Center, Atten: HIV Research Unit
Dallas, Texas, United States
Site recruitment: Not reported
Research Access Network
Houston, Texas, United States
Site recruitment: Not reported
Virginia Mason Medical Center
Seattle, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableTerminatedOBSERVATIONAL

Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®

ClinicalTrials.gov · NCT01579695 · Registry updated: 2018-09-11

Condition / research focus: HIV
Sponsor: Theratechnologies
Countries with listed sites: United States
Registry dates and results: Start: 2013-02. Completion: 2018-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin for injection (drug)

Where the study takes place — 31 listed sites

Franco Felizarta, MD
Bakersfield, California, United States
Site recruitment: Not reported
Pacific Coast Medical Group
Fountain Valley, California, United States
Site recruitment: Not reported
University of California CARE Clinic, Los Angeles
Los Angeles, California, United States
Site recruitment: Not reported
Tower Infectious Diseases Medical Associates
Los Angeles, California, United States
Site recruitment: Not reported
Oasis Clinic
Los Angeles, California, United States
Site recruitment: Not reported
VAMC, Infectious Disease Section 111W
San Francisco, California, United States
Site recruitment: Not reported
Dupont Circle Physician's Group
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Capital Medical Associates, PC
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Gary J. Richmond, M.D., PA
Fort Lauderdale, Florida, United States
Site recruitment: Not reported
The Kinder Medical Group-AHF
Miami, Florida, United States
Site recruitment: Not reported
Orange County Health Department
Orlando, Florida, United States
Site recruitment: Not reported
Orange County Health Department
Orlando, Florida, United States
Site recruitment: Not reported
Rowan Tree Medical, P.A.
Wilton Manors, Florida, United States
Site recruitment: Not reported
Absolute Care Medical Center
Atlanta, Georgia, United States
Site recruitment: Not reported
Northstar Medical Center
Chicago, Illinois, United States
Site recruitment: Not reported
Southern Illnois University School of Medicine
Springfield, Illinois, United States
Site recruitment: Not reported
Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
The Researth Institute
Springfield, Massachusetts, United States
Site recruitment: Not reported
Be Well Medical Center, P.C
Berkley, Michigan, United States
Site recruitment: Not reported
Southhampton Clinical Research, Inc. d.b.a. Central West Clinical Research
St Louis, Missouri, United States
Site recruitment: Not reported
Southampton Healthcare, Inc.
St Louis, Missouri, United States
Site recruitment: Not reported
South Jersey Unfectious Disease
Somers Point, New Jersey, United States
Site recruitment: Not reported
University at Buffalo, State University of NY, Erie County Medical Center
Buffalo, New York, United States
Site recruitment: Not reported
Ricky K. Hsu, MD, PC
New York, New York, United States
Site recruitment: Not reported
Summa Health Care System
Akron, Ohio, United States
Site recruitment: Not reported
Virginia Mason Medical Center
Tulsa, Oklahoma, United States
Site recruitment: Not reported
Reading Hospital and Medical Center
West Reading, Pennsylvania, United States
Site recruitment: Not reported
St. Hope Foundation, Inc.
Bellaire, Texas, United States
Site recruitment: Not reported
Dallas VA Medical Center
Dallas, Texas, United States
Site recruitment: Not reported
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States
Site recruitment: Not reported
Virginia Mason Medical Center
Seattle, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

ClinicalTrials.gov · NCT00675506 · Registry updated: 2017-12-13

Condition / research focus: Abdominal Obesity; Growth Hormone Deficiency
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2008-07. Completion: 2012-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Growth hormone releasing hormone (GHRH) 1-44 (drug) — also listed as: TH9507
Placebo (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effects of Growth Hormone Releasing Hormone in HIV

ClinicalTrials.gov · NCT01263717 · Registry updated: 2017-10-30

Condition / research focus: HIV; HIV Lipodystrophy
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2010-12. Completion: 2014-02 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

tesamorelin (drug) — also listed as: Egrifta, growth hormone releasing hormone, TH9507
placebo (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableWithdrawnOBSERVATIONAL

Egrifta Replacement and Sleep Disordered Breathing

ClinicalTrials.gov · NCT01788462 · Registry updated: 2017-03-03

Condition / research focus: Lipodystrophy
Sponsor: Johns Hopkins University
Countries with listed sites: United States
Registry dates and results: Start: 2012-05. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (Egrifta) (drug) — also listed as: Egrifta TM

Where the study takes place — 1 listed sites

Johns Hopkins Sleep Disorders Center
Baltimore, Maryland, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableWithdrawnINTERVENTIONAL

Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue

ClinicalTrials.gov · NCT01632592 · Registry updated: 2014-01-24

Condition / research focus: Abdominal Obesity
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2014-01. Completion: 2014-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effects of Short-term Growth Hormone in HIV-infected Patients

ClinicalTrials.gov · NCT00795210 · Registry updated: 2014-01-08

Condition / research focus: HIV Lipodystrophy
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2009-02. Completion: 2012-11 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Growth hormone (drug) — also listed as: rhGH from Teva Pharmaceuticals
Growth Hormone Releasing Hormone (drug)

Where the study takes place — 1 listed sites

MGH
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

SMART: Somatotrophics, Memory, and Aging Research Trial

ClinicalTrials.gov · NCT00257712 · Registry updated: 2013-12-19

Condition / research focus: Aging; Mild Cognitive Impairment
Sponsor: University of Washington
Countries with listed sites: United States
Registry dates and results: Start: 2006-02. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TH9507 human growth hormone releasing hormone (GHRH) (drug)

Where the study takes place — 1 listed sites

University of Washington
Seattle, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

24 matching registry records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 17:39 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 2RecruitingINTERVENTIONAL

Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV

ClinicalTrials.gov · NCT06554717 · Registry updated: 2026-05-19

Condition / research focus: HIV-1-infection; Frailty; Impaired Physical Function; Abdominal Obesity; Aging
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2025-07-10. Completion: 2028-12-01 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug) — also listed as: Egrifta, TH9507, growth hormone-releasing hormone analogue
Placebo (drug)
Exercise (behavioral)

Where the study takes place — 2 listed sites

University of Colorado - Anschutz Medical Campus
Aurora, Colorado, United States
Site recruitment: Recruiting
Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Body Composition and Adipose Tissue in HIV

ClinicalTrials.gov · NCT03226821 · Registry updated: 2026-05-19

Condition / research focus: HIV Lipodystrophy Syndrome; Growth Hormone Deficiency; Body Composition
Sponsor: Columbia University
Countries with listed sites: United States
Registry dates and results: Start: 2018-02-07. Completion: 2025-04-30 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug) — also listed as: Egrifta

Where the study takes place — 1 listed sites

Neuroendocrine Unit and Pituitary Center, Columbia University
New York, New York, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Tesamorelin for Reduction of Liver Fat in Adults With Fatty Liver Disease (Mock Study)

ClinicalTrials.gov · NCT07481734 · Registry updated: 2026-03-19

Condition / research focus: Metabolic Associated Steatotic Liver Disease; Nonalcoholic Steatohepatitis; Hepatic Steatosis
Sponsor: Hudson Biotech
Countries with listed sites: China
Registry dates and results: Start: 2026-02-02. Completion: 2028-02-17 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug)
Placebo (drug)
Standardized lifestyle counseling (behavioral)

Where the study takes place — 1 listed sites

Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons

ClinicalTrials.gov · NCT02572323 · Registry updated: 2026-03-12

Condition / research focus: Mild Cognitive Impairment
Sponsor: University of California, San Diego
Countries with listed sites: United States
Registry dates and results: Start: 2017-02-15. Completion: 2023-10-15 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug) — also listed as: Egrifta

Where the study takes place — 4 listed sites

Keck School of Medicine of the University of Southern California
Los Angeles, California, United States
Site recruitment: Not reported
PalmTree
Palm Springs, California, United States
Site recruitment: Not reported
HIV Neurobehavioral Research Program (HNRP)
San Diego, California, United States
Site recruitment: Not reported
University of California, San Francisco
San Francisco, California, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk

ClinicalTrials.gov · NCT03375788 · Registry updated: 2025-11-20

Condition / research focus: Non-Alcoholic Fatty Liver Disease; Obesity; Obesity, Abdominal; Liver Fat; Fatty Liver
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2019-01-17. Completion: 2025-01-10 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug) — also listed as: Egrifta, TH9507, Growth Hormone Releasing Hormone Analog
Identical Placebo (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury

ClinicalTrials.gov · NCT03150511 · Registry updated: 2025-11-12

Condition / research focus: Peripheral Nerve Injuries
Sponsor: Johns Hopkins University
Countries with listed sites: United States
Registry dates and results: Start: 2018-06-01. Completion: 2027-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin 2 Milligrams (MG) (drug) — also listed as: Egrifta

Where the study takes place — 1 listed sites

Sami Tuffaha
Baltimore, Maryland, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

ClinicalTrials.gov · NCT00608023 · Registry updated: 2022-09-30

Condition / research focus: Lipodystrophy; HIV Infections
Sponsor: Theratechnologies
Countries with listed sites: Belgium · Canada · France · Spain · United Kingdom · United States
Registry dates and results: Start: 2007-08. Completion: 2008-10 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug) — also listed as: Egrifta
Placebo for Tesamorelin (drug)

Where the study takes place — 47 listed sites

University of Alabama at Birmingham
Birmingham, Alabama, United States
Site recruitment: Not reported
Body Positive Inc.
Phoenix, Arizona, United States
Site recruitment: Not reported
Somero, Michael
Indio, California, United States
Site recruitment: Not reported
UCLA School of Medicine
Los Angeles, California, United States
Site recruitment: Not reported
Office of Dr. Michael Somero
Palm Springs, California, United States
Site recruitment: Not reported
University of California
San Francisco, California, United States
Site recruitment: Not reported
Kaiser Permanente
San Francisco, California, United States
Site recruitment: Not reported
UCSF/VA Medical Center
San Francisco, California, United States
Site recruitment: Not reported
AIDS Research Alliance
West Hollywood, California, United States
Site recruitment: Not reported
Denver Public Health Department
Denver, Colorado, United States
Site recruitment: Not reported
Office of Dr. Gary Richmond
Fort Lauderdale, Florida, United States
Site recruitment: Not reported
Hendry/Glades County Health Departments
LaBelle, Florida, United States
Site recruitment: Not reported
Infectious Disease Research Institute Inc.
Tampa, Florida, United States
Site recruitment: Not reported
AIDS Research Consortium Atlanta (ARCA)
Atlanta, Georgia, United States
Site recruitment: Not reported
Northern Healthcare
Chicago, Illinois, United States
Site recruitment: Not reported
Northstar Medical
Chicago, Illinois, United States
Site recruitment: Not reported
Indiana University Department of Medicine
Indianapolis, Indiana, United States
Site recruitment: Not reported
Tufts University School of Medicine
Boston, Massachusetts, United States
Site recruitment: Not reported
Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
The Research Institute
Springfield, Massachusetts, United States
Site recruitment: Not reported
ID Associates
Hillsborough, New Jersey, United States
Site recruitment: Not reported
AIDS Community Research Initiative of America
New York, New York, United States
Site recruitment: Not reported
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Site recruitment: Not reported
University Hospitals of Cleveland
Cleveland, Ohio, United States
Site recruitment: Not reported
Central Texas Clinical Research
Austin, Texas, United States
Site recruitment: Not reported
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States
Site recruitment: Not reported
Swedish Medical Center
Seattle, Washington, United States
Site recruitment: Not reported
C. H. U. Sart-Tilman
Liège, Belgium
Site recruitment: Not reported
St-Paul's Hospital
Vancouver, British Columbia, Canada
Site recruitment: Not reported
McMaster University Health Sciences Centre
Hamilton, Ontario, Canada
Site recruitment: Not reported
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Site recruitment: Not reported
Toronto General Hospital
Toronto, Ontario, Canada
Site recruitment: Not reported
Centre Hospitalier Universitaire de Santé de l'Estrie
Fleurimont, Quebec, Canada
Site recruitment: Not reported
Montreal General Hospital
Montreal, Quebec, Canada
Site recruitment: Not reported
Groupe de Recherche en Rhumatologie et maladies osseuses
Ste-Foy, Quebec, Canada
Site recruitment: Not reported
Hôpital Hotel Dieu Lyon
Lyon, France
Site recruitment: Not reported
Hotel Dieu
Nantes, France
Site recruitment: Not reported
Hopital Europeen Georges Pompidou
Paris, France
Site recruitment: Not reported
Hopital Necker
Paris, France
Site recruitment: Not reported
Hosp. Ramon y Cajal
Madrid, Spain
Site recruitment: Not reported
Hosp. Clinico San Carlos
Madrid, Spain
Site recruitment: Not reported
Hosp.C.U.de Santiago
Santiago de Compostela, Spain
Site recruitment: Not reported
BSUH NHS Trust
Brighton, United Kingdom
Site recruitment: Not reported
St Georges Hospital
London, United Kingdom
Site recruitment: Not reported
Royal Free Hospital
London, United Kingdom
Site recruitment: Not reported
Chelsea and Westminster Hospital
London, United Kingdom
Site recruitment: Not reported
St Mary's NHS Trust
London, United Kingdom
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Growth Hormone Dynamics and Cardiac Steatosis in HIV

ClinicalTrials.gov · NCT03826160 · Registry updated: 2022-07-19

Condition / research focus: Human Immunodeficiency Virus; Lipodystrophy; Cardiac Disease
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2019-01-30. Completion: 2022-04-19 (may be estimated). No results posted in this registry response.

Products and interventions (0)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2TerminatedINTERVENTIONAL

Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting

ClinicalTrials.gov · NCT01388920 · Registry updated: 2022-03-18

Condition / research focus: Chronic Obstructive Pulmonary Disease (COPD)
Sponsor: Theratechnologies
Countries with listed sites: No country reported
Registry dates and results: Start: 2011-09. Completion: 2011-12 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug)
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Tesamorelin Effects on Liver Fat and Histology in HIV

ClinicalTrials.gov · NCT02196831 · Registry updated: 2020-01-27

Condition / research focus: Human Immunodeficiency Virus (HIV); Nonalcoholic Fatty Liver Disease (NAFLD); Nonalcoholic Steatohepatitis (NASH)
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2015-07-01. Completion: 2019-07-24 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

tesamorelin (drug) — also listed as: Egrifta
Placebo (drug)

Where the study takes place — 2 listed sites

National Institutes of Health
Bethesda, Maryland, United States
Site recruitment: Not reported
Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2WithdrawnINTERVENTIONAL

Impact of GHRH on Sleep Promotion and Endocrine Regulation in Service Members Who Sustained a Traumatic Brain Injury and Have Current Insomnia

ClinicalTrials.gov · NCT02931474 · Registry updated: 2019-11-19

Condition / research focus: Sleep Disorder; Traumatic Brain Injury
Sponsor: National Institute of Nursing Research (NINR)
Countries with listed sites: No country reported
Registry dates and results: Start: 2016-10-06. Completion: 2017-03-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug)
Placebo (other)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

The Effect of Growth Hormone Releasing Hormone on Cognitive Function in Individuals With Mild Cognitive Impairment

ClinicalTrials.gov · NCT02553603 · Registry updated: 2019-11-04

Condition / research focus: Mild Cognitive Impairment
Sponsor: The University of Texas Medical Branch, Galveston
Countries with listed sites: United States
Registry dates and results: Start: 2017-07-18. Completion: 2019-01-17 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Growth Hormone Releasing Hormone (GHRH) (drug) — also listed as: Egrifta, tesamorelin
Placebo Growth Hormone Releasing Hormone (drug) — also listed as: Placebo

Where the study takes place — 1 listed sites

The University of Texas Medical Branch
Galveston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

ClinicalTrials.gov · NCT01591902 · Registry updated: 2018-09-11

Condition / research focus: Diabetic Retinopathy; HIV
Sponsor: Theratechnologies
Countries with listed sites: United States
Registry dates and results: Start: 2012-06. Completion: 2018-08 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug)
Placebo-Control (drug)

Where the study takes place — 24 listed sites

Southwest Center for HIV/AIDS
Phoenix, Arizona, United States
Site recruitment: Not reported
Spectrum Medical Group
Phoenix, Arizona, United States
Site recruitment: Not reported
5P21 Rand Schrader Clinic
Los Angeles, California, United States
Site recruitment: Not reported
University of California CARE Clinic, Los Angeles
Los Angeles, California, United States
Site recruitment: Not reported
Palmtree Clinical Research, Inc.
Palm Springs, California, United States
Site recruitment: Not reported
UCSD Antiviral Research Center
San Diego, California, United States
Site recruitment: Not reported
VAMC, Infectious Disease Section 111W
San Francisco, California, United States
Site recruitment: Not reported
Capital Medical Associates, PC
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Gary J. Richmond, M.D., PA
Fort Lauderdale, Florida, United States
Site recruitment: Not reported
Orange County Health Department
Orlando, Florida, United States
Site recruitment: Not reported
Triple O Research Institute
West Palm Beach, Florida, United States
Site recruitment: Not reported
Rowan Tree Medical , P.A.
Wilton Manors, Florida, United States
Site recruitment: Not reported
Be Well Medical Center, P.C.
Berkley, Michigan, United States
Site recruitment: Not reported
Southampton Clinical Research, Inc d.b.a. Central West Clinical Research
St Louis, Missouri, United States
Site recruitment: Not reported
Southampton Healthcare, Inc.
St Louis, Missouri, United States
Site recruitment: Not reported
South Jersey Infectious Disease
Somers Point, New Jersey, United States
Site recruitment: Not reported
Harold Hamm Diabetes Center at the University of Oklahoma
Oklahoma City, Oklahoma, United States
Site recruitment: Not reported
Fanno Creek Clinic, LLC
Portland, Oregon, United States
Site recruitment: Not reported
Central Texas Clinical Research
Austin, Texas, United States
Site recruitment: Not reported
St. Hope Foundation, Inc.
Bellaire, Texas, United States
Site recruitment: Not reported
Dallas VA Medical Center
Dallas, Texas, United States
Site recruitment: Not reported
UT Southwestern Medical Center, Atten: HIV Research Unit
Dallas, Texas, United States
Site recruitment: Not reported
Research Access Network
Houston, Texas, United States
Site recruitment: Not reported
Virginia Mason Medical Center
Seattle, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableTerminatedOBSERVATIONAL

Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®

ClinicalTrials.gov · NCT01579695 · Registry updated: 2018-09-11

Condition / research focus: HIV
Sponsor: Theratechnologies
Countries with listed sites: United States
Registry dates and results: Start: 2013-02. Completion: 2018-08 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin for injection (drug)

Where the study takes place — 31 listed sites

Franco Felizarta, MD
Bakersfield, California, United States
Site recruitment: Not reported
Pacific Coast Medical Group
Fountain Valley, California, United States
Site recruitment: Not reported
University of California CARE Clinic, Los Angeles
Los Angeles, California, United States
Site recruitment: Not reported
Tower Infectious Diseases Medical Associates
Los Angeles, California, United States
Site recruitment: Not reported
Oasis Clinic
Los Angeles, California, United States
Site recruitment: Not reported
VAMC, Infectious Disease Section 111W
San Francisco, California, United States
Site recruitment: Not reported
Dupont Circle Physician's Group
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Capital Medical Associates, PC
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
Gary J. Richmond, M.D., PA
Fort Lauderdale, Florida, United States
Site recruitment: Not reported
The Kinder Medical Group-AHF
Miami, Florida, United States
Site recruitment: Not reported
Orange County Health Department
Orlando, Florida, United States
Site recruitment: Not reported
Orange County Health Department
Orlando, Florida, United States
Site recruitment: Not reported
Rowan Tree Medical, P.A.
Wilton Manors, Florida, United States
Site recruitment: Not reported
Absolute Care Medical Center
Atlanta, Georgia, United States
Site recruitment: Not reported
Northstar Medical Center
Chicago, Illinois, United States
Site recruitment: Not reported
Southern Illnois University School of Medicine
Springfield, Illinois, United States
Site recruitment: Not reported
Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported
The Researth Institute
Springfield, Massachusetts, United States
Site recruitment: Not reported
Be Well Medical Center, P.C
Berkley, Michigan, United States
Site recruitment: Not reported
Southhampton Clinical Research, Inc. d.b.a. Central West Clinical Research
St Louis, Missouri, United States
Site recruitment: Not reported
Southampton Healthcare, Inc.
St Louis, Missouri, United States
Site recruitment: Not reported
South Jersey Unfectious Disease
Somers Point, New Jersey, United States
Site recruitment: Not reported
University at Buffalo, State University of NY, Erie County Medical Center
Buffalo, New York, United States
Site recruitment: Not reported
Ricky K. Hsu, MD, PC
New York, New York, United States
Site recruitment: Not reported
Summa Health Care System
Akron, Ohio, United States
Site recruitment: Not reported
Virginia Mason Medical Center
Tulsa, Oklahoma, United States
Site recruitment: Not reported
Reading Hospital and Medical Center
West Reading, Pennsylvania, United States
Site recruitment: Not reported
St. Hope Foundation, Inc.
Bellaire, Texas, United States
Site recruitment: Not reported
Dallas VA Medical Center
Dallas, Texas, United States
Site recruitment: Not reported
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States
Site recruitment: Not reported
Virginia Mason Medical Center
Seattle, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese

ClinicalTrials.gov · NCT00675506 · Registry updated: 2017-12-13

Condition / research focus: Abdominal Obesity; Growth Hormone Deficiency
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2008-07. Completion: 2012-01 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Growth hormone releasing hormone (GHRH) 1-44 (drug) — also listed as: TH9507
Placebo (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effects of Growth Hormone Releasing Hormone in HIV

ClinicalTrials.gov · NCT01263717 · Registry updated: 2017-10-30

Condition / research focus: HIV; HIV Lipodystrophy
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2010-12. Completion: 2014-02 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

tesamorelin (drug) — also listed as: Egrifta, growth hormone releasing hormone, TH9507
placebo (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableWithdrawnOBSERVATIONAL

Egrifta Replacement and Sleep Disordered Breathing

ClinicalTrials.gov · NCT01788462 · Registry updated: 2017-03-03

Condition / research focus: Lipodystrophy
Sponsor: Johns Hopkins University
Countries with listed sites: United States
Registry dates and results: Start: 2012-05. Completion: Not reported (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (Egrifta) (drug) — also listed as: Egrifta TM

Where the study takes place — 1 listed sites

Johns Hopkins Sleep Disorders Center
Baltimore, Maryland, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableWithdrawnINTERVENTIONAL

Abdominal Obesity, Cardiovascular Inflammation, and Effects of Growth Hormone Releasing Hormone Analogue

ClinicalTrials.gov · NCT01632592 · Registry updated: 2014-01-24

Condition / research focus: Abdominal Obesity
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2014-01. Completion: 2014-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Tesamorelin (drug)
Placebo (drug)

Where the study takes place — 1 listed sites

Massachusetts General Hospital
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Effects of Short-term Growth Hormone in HIV-infected Patients

ClinicalTrials.gov · NCT00795210 · Registry updated: 2014-01-08

Condition / research focus: HIV Lipodystrophy
Sponsor: Massachusetts General Hospital
Countries with listed sites: United States
Registry dates and results: Start: 2009-02. Completion: 2012-11 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Growth hormone (drug) — also listed as: rhGH from Teva Pharmaceuticals
Growth Hormone Releasing Hormone (drug)

Where the study takes place — 1 listed sites

MGH
Boston, Massachusetts, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

SMART: Somatotrophics, Memory, and Aging Research Trial

ClinicalTrials.gov · NCT00257712 · Registry updated: 2013-12-19

Condition / research focus: Aging; Mild Cognitive Impairment
Sponsor: University of Washington
Countries with listed sites: United States
Registry dates and results: Start: 2006-02. Completion: 2011-12 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TH9507 human growth hormone releasing hormone (GHRH) (drug)

Where the study takes place — 1 listed sites

University of Washington
Seattle, Washington, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →